NCT01912040撤回不适用
A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Safety profile of the 123Iodine MIBG
研究概览
简要总结
Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.
详细描述
We will be assessing for adverse reactions of patients injected with locally manufactured 123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any potential immediate side effects.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 1 Month 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with potential Adrenergic pathology
排除标准
- •Pregnant or breast feeding females
- •Hypersensitivity to MIBG
研究组 & 干预措施
Patients
Administration of 123Iodine MIBG to the patients referred .
干预措施: Administration of 123Iodine MIBG (Drug)
结局指标
主要结局
Safety profile of the 123Iodine MIBG
时间窗: BP and Heart rate for 24 hours after injection.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
MIBG for Refractory Neuroblastoma and PheochromocytomaRelapsed NeuroblastomaMetastatic PheochromocytomaNCT01850888Masonic Cancer Center, University of Minnesota15
Unknown
1 期
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#Relapsed/Refractory Multiple MyelomaNCT05266768Chunrui Li36
已完成
1 期
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#Relapsed/Refractory Multiple MyelomaNCT05270928The First Affiliated Hospital of Soochow University6
已完成
1 期
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid TumorsCancer, Solid TumorNCT02937116Innovent Biologics (Suzhou) Co. Ltd.233
已完成
1 期
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid ArthritisRheumatoid ArthritisNCT00771329Biogen53